Chordia Therapeutics Inc. (190A.T)
Tokyo · JPY · Healthcare · Biotechnology
¥50 (+0.00%) as of
Key statistics
- Market cap
- 3.76B
- EPS (TTM)
- -19.74
- Dividend yield
- 0.00%
- 52-week range
- 47.00 – 179.00
- Beta
- 3.07
- Profit margin
- 0.00%
- Volume
- 51.40k
About Chordia Therapeutics Inc.
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Fujisawa, Japan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.